Abstract
INTRODUCTION
Plasma biomarkers sensitive to Alzheimer’s disease (AD) proteinopathy prior to the onset of dementia have significant implications for early detection.
METHODS
In 304 individuals without dementia, we investigated whether C2N Diagnostics’ mass spectrometry (MS)-based plasma biomarkers (amyloid beta 42/40, %phosphorylated tau [p-tau]181, and %p-tau217) and amyloid probability scores (APS, PrecivityAD and APS2, PrecivityAD2) are associated with brain amyloid, brain tau, or preclinical cognitive decline.
RESULTS
In this cohort study, %p-tau217 and the APS2 had high discriminative accuracy (area under the curve > 0.93) for identifying elevated brain amyloid and tau and were associated with faster preclinical cognitive decline. Using %p-tau217 or the APS2 in a theoretical AD trial screening scenario reduced amyloid positron emission tomography imaging costs up to 41% or 45%, respectively.
DISCUSSION
These findings suggest that C2N Diagnostics’ MS-based plasma biomarkers can detect brain amyloid and tau with high accuracy prior to dementia and could aid in identifying candidates for clinical trials or therapeutic intervention.
Highlights
C2N plasma biomarkers differentiated Alzheimer’s disease proteinopathy status prior to dementia.
Plasma %phosphorylated tau (p-tau)217 and the C2N Diagnostics PrecivityAD2 (APS2) were concordant with amyloid and tau positron emission tomography status.
Plasma %p-tau217 and the APS2 were associated with preclinical cognitive decline.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Karly A. Cody,
Lianlian Du,
Rachel L. Studer,
Erin M. Jonaitis,
Sanjay Asthana,
Bradley T. Christian,
Nathaniel A. Chin,
Kris M. Kirmess,
Matthew R. Meyer,
Kevin E. Yarasheski,
Tim West,
Philip B. Verghese,
Joel B. Braunstein,
Tobey J. Betthauser,
Rebecca E. Langhough,
Sterling C. Johnson | March 20, 2025